Low molecular weight thyroid stimulating hormone receptor (tshr) agonists
AssigneesForschungsverbund Berlin E.V., The Government of the United States of America as represented by the Secretary of the Department of
InventorsMarvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
Life of this patent
Estimating the term…
Abstract
Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.
Claims20
A compound having formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- (a) R1-R4 are each independently H, hydroxyl, alkyl, alkoxy, aminocarbonyl, or halogen;
- R5 is H, alkyl, aralkyl, or aminocarbonyl;
- A represents —N═C(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above) or —NH—CH(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above);
- R15 is represented by formula II:
- wherein:
- R6-R9 are each independently H, hydroxyl, alkyl, or alkoxy;
- R10, R11, R13 and R14 are each independently H;
- R12 is acetamido;
- and
- X is O, S or N(H);
- with the proviso that the compound of formula I is not
- or
- (b) R1-R3 are each independently H, hydroxyl, alkyl, alkoxy, aminocarbonyl, or halogen;
- R4 is hydroxyl;
- R5 is H, alkyl, aryl, aralkyl, or aminocarbonyl;
- A represents —N═C(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above) or —NH—CH(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above);
- R15 is represented by formula II:
- wherein:
- R6-R9 are each independently H, hydroxyl, alkyl, or alkoxy;
- R10, R11, R13 and R14 are each independently H;
- R12 is acetamido;
- and
- X is O, S or N(H);
- or
- (c) R1-R4 are each independently H, hydroxyl, alkyl, alkoxy, aminocarbonyl, or halogen;
- R5 is H, alkyl, aryl, aralkyl, or aminocarbonyl;
- A represents —N═C(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above);
- R15 is represented by formula II:
- wherein:
- R6-R9 are each independently H, hydroxyl, alkyl, or alkoxy;
- R10, R11, R13 and R14 are each independently H;
- R12 is acetamido;
- and
- X is O, S or N(H).
A method for detecting thyroid cancer in a subject, comprising administering to the subject in need thereof a diagnostically effective amount of at least one compound of formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R4 are each independently H, hydroxyl, alkyl, alkoxy, aminocarbonyl, or halogen;
- R5 is H, alkyl, aryl, aralkyl, or aminocarbonyl;
- A represents —N═C(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above) or —NH—CH(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above);
- R15 is represented by formula II:
- wherein:
- R6-R9 are each independently H, hydroxyl, alkyl, or alkoxy;
- R10, R11, R13 and R14 are each independently H;
- R12 is acetamido;
- and
- X is O, S or N(H).
A method for treating thyroid cancer in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of at least one compound having a formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R4 are each independently H, hydroxyl, alkyl, alkoxy, aminocarbonyl, or halogen;
- R5 is H, alkyl, aryl, aralkyl, or aminocarbonyl;
- A represents —N═C(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above) or —NH—CH(R15)— (wherein a bond at the left end bonds to the benzene ring of formula I above and a bond at the right end bonds to the nitrogen heteroatom of formula I above);
- R15 is represented by formula II:
- wherein:
- R6-R9 are each independently H, hydroxyl, alkyl, or alkoxy;
- R10, R11, R13 and R14 are each independently H;
- R12 is acetamido;
- and
- X is O, S or N(H).
The method of claim 21, further comprising co-administering radioiodine with the compound of formula I to ablate thyroid remnants following near-total thyroidectomy in a subject without evidence of metastatic disease.
Dependencies are inferred from the claim text.